ARD 201
Alternative Names: ARD-101 plus DPP-4 inhibitor; ARD-201Latest Information Update: 22 Aug 2025
At a glance
- Originator Aardvark Therapeutics
- Class Obesity therapies; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 12 Aug 2025 Pharmacodynamics data from a preclinical studies released by Aardvark Therapeutics
- 12 Aug 2025 Aardvark Therapeutics plans a phase II POWER (Prevention Of WEight Regain) trial for Obesity in the second half of 2025
- 12 Aug 2025 Aardvark Therapeutics plans a phase II STRENGTH (Sitagliptin and TAS2R for weight Reduction with Exercise, Nutrition, and GLP-1RA Trial and Hunger assessment) trial for Obesity in the first half of 2026